According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, Jefferies Group reaffirmed a hold rating on shares of Enzymotec in a research report on Thursday, August 4th.
Enzymotec (NASDAQ:ENZY) opened at 7.4499 on Tuesday. The firm’s 50-day moving average price is $7.24 and its 200 day moving average price is $8.11. Enzymotec has a 52-week low of $6.60 and a 52-week high of $10.32. The firm has a market cap of $169.25 million, a price-to-earnings ratio of 39.2100 and a beta of 1.27.
Enzymotec (NASDAQ:ENZY) last issued its earnings results on Tuesday, August 9th. The company reported $0.04 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by $0.04. Enzymotec had a return on equity of 3.12% and a net margin of 8.37%. The company earned $15 million during the quarter, compared to analysts’ expectations of $14.90 million. During the same period in the previous year, the company earned $0.11 EPS. Enzymotec’s quarterly revenue was down 12.7% on a year-over-year basis. On average, equities research analysts forecast that Enzymotec will post $0.27 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Van ECK Associates Corp increased its position in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock worth $106,000 after buying an additional 706 shares in the last quarter. Geode Capital Management LLC acquired a new position in shares of Enzymotec during the first quarter worth approximately $114,000. TFS Capital LLC acquired a new position in shares of Enzymotec during the second quarter worth approximately $153,000. BlackRock Institutional Trust Company N.A. increased its position in shares of Enzymotec by 13.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 19,015 shares of the company’s stock worth $172,000 after buying an additional 2,318 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its position in shares of Enzymotec by 68.0% in the second quarter. State of New Jersey Common Pension Fund D now owns 22,021 shares of the company’s stock worth $184,000 after buying an additional 8,915 shares in the last quarter. 36.20% of the stock is owned by hedge funds and other institutional investors.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.